| 17.14 0.19 (1.12%) | 09-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.73 | 1-year : | 21.56 |
| Resists | First : | 17.75 | Second : | 18.46 |
| Pivot price | 17.13  |
|||
| Supports | First : | 16.6 | Second : | 13.81 |
| MAs | MA(5) : | 16.95 |
MA(20) : | 17.34 |
| MA(100) : | 16.45 |
MA(250) : | 16.41 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.8 |
D(3) : | 19.3 |
| RSI | RSI(14): 50.1 |
|||
| 52-week | High : | 18.91 | Low : | 13.76 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BLCO ] has closed below upper band by 49.5%. Bollinger Bands are 13.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.22 - 17.29 | 17.29 - 17.36 |
| Low: | 16.55 - 16.62 | 16.62 - 16.7 |
| Close: | 17.02 - 17.15 | 17.15 - 17.28 |
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
Mon, 28 Sep 2026
A former director plans to sell 4,500 Bausch & Lomb (BLCO) shares from stock vesting. - Stock Titan
Fri, 25 Sep 2026
Bausch Lomb (TSX:BLCO): Eye Health Growth In Healthcare - Kalkine Media
Fri, 11 Sep 2026
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser - Business Wire
Wed, 09 Sep 2026
Leerink Partners Initiates Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $24 - Moomoo
Thu, 06 Aug 2026
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance - BioSpace
Thu, 06 Aug 2026
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 357 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 87.3 (%) |
| Held by Institutions | 11.1 (%) |
| Shares Short | 3,160 (K) |
| Shares Short P.Month | 3,180 (K) |
| EPS | -0.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.09 |
| Profit Margin | -3.3 % |
| Operating Margin | 7.7 % |
| Return on Assets (ttm) | 1.8 % |
| Return on Equity (ttm) | -2.6 % |
| Qtrly Rev. Growth | 9.1 % |
| Gross Profit (p.s.) | 9.15 |
| Sales Per Share | 14.89 |
| EBITDA (p.s.) | 2.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 458 (M) |
| Levered Free Cash Flow | 323 (M) |
| PE Ratio | -35.71 |
| PEG Ratio | 0.8 |
| Price to Book value | 0.94 |
| Price to Sales | 1.15 |
| Price to Cash Flow | 13.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|